Cancer
Alkylating agents (cyclophosphamide, temozolomide, dacarbazine)
Drugs that attach alkyl groups to DNA, cross-linking or mispairing it; cyclophosphamide is used in breast cancer and lymphomas, temozolomide in glioblastoma, dacarbazine in Hodgkin lymphoma.
Mechanism of action
- They form reactive intermediates that alkylate DNA bases, mostly guanine N7 or O6.
- Bifunctional agents (cyclophosphamide) cross-link the strands; methylating agents (temozolomide, dacarbazine) cause mispairing and strand breaks.
- Cyclophosphamide is activated in the liver; its by-product acrolein irritates the bladder.
- Glioblastomas with a silenced MGMT gene cannot repair temozolomide damage and respond better.
Molecular targets
- DNA bases (guanine): Alkylated
Drugs in Alkylating agents (cyclophosphamide, temozolomide, dacarbazine)
Nitrogen mustard
- Cyclophosphamide (Prodrug activated by the liver.)
Triazenes (methylating agents)
- Temozolomide (By mouth; crosses the blood–brain barrier.)
- Dacarbazine (In ABVD.)
Therapeutic uses
- Glioblastoma: temozolomide with radiotherapy, then alone
- Hodgkin lymphoma (dacarbazine in ABVD)
- Breast cancer and non-Hodgkin lymphomas (cyclophosphamide)
- Severe autoimmune disease (cyclophosphamide)
Diseases it treats
Adverse effects
- Myelosuppression
- Nausea and vomiting
- Haemorrhagic cystitis (cyclophosphamide; prevented with mesna and fluids)
- Infertility and secondary leukaemias
Contraindications by condition
- Pregnancy (Contraindicated): They are teratogenic.
- Severe bone marrow suppression (Use with care): They suppress the marrow further.
- Liver cirrhosis (Use with care): Both are activated by the liver.
Written from
- Lippincott Illustrated Reviews: Pharmacology, 7th ed., Ch. 35, Anticancer Drugs, Alkylating agents
- Basic & Clinical Pharmacology (Katzung), 14th ed., Ch. 54, Cancer Chemotherapy, Alkylating agents
Educational reference. Not medical advice, diagnosis or treatment.